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Abstract
Purpose Ebola virus disease (EVD) is a viral
hemorrhagic fever that is highly transmissible and all too
often rapidly fatal. Recent outbreaks in West Africa reveal
that this infection has the potential to be transmitted
worldwide. Anesthesiologists and intensivists, due to their
training in the management of the critically ill, may be
called upon to assist in the management of these patients.
The focus of this brief review is on the epidemiology,
pathogenesis, and management of patients with EVD.
Source Review of the current literature.
Principal findings Ebola virus disease causes severe
diarrhea, electrolyte disturbances and other major end-
organ dysfunction. Early aggressive resuscitation may
reduce the mortality of this disease. There is presently no
available vaccine nor cure, with experimental therapies
having yielded limited success. Personal protective
equipment (PPE) is necessary for all patient contact, and
enhanced PPE is required for all aerosol-generating
medical procedures.
Conclusion Anesthesiologists and intensivists may be
called upon to manage patients with EVD. It is important
that these clinicians have an appreciation for the
epidemiology and pathogenesis of this disease and for
the proper utilization of PPE when treating these patients.
Re´sume´
Objectif La maladie a` virus Ebola (MVE) est une fie`vre
virale he´morragique hautement transmissible et, beaucoup
trop souvent, rapidement mortelle. Les re´centes e´pide´mies
survenues en Afrique de l’Ouest de´montrent que cette
infection a le potentiel de se re´pandre dans le monde
entier. Compte tenu de leur formation a` la gestion de
personnes gravement malades, les anesthe´siologistes
peuvent eˆtre appele´s a` aider a` la prise en charge de ces
patients. Cette courte synthe`se fait le point sur
l’e´pide´miologie, la pathoge´nie et la gestion des patients
atteints de MVE.
Source Revue de la litte´rature actuelle.
Constatations principales La maladie a` virus Ebola
provoque une diarrhe´e se´ve`re et des de´sordres
e´lectrolytiques. Une re´animation pre´coce, agressive peut
re´duire la mortalite´ lie´e a` cette maladie. Il n’y a pas de
traitement, mais des the´rapies expe´rimentales ont e´te´
tente´es avec un succe`s limite´ chez des patients infecte´s.
Un e´quipement de protection individuel (EPI) est
ne´cessaire pour tous les contacts avec le patient. Un EPI
renforce´ est requis pour toutes les proce´dures me´dicales
ge´ne´rant un ae´rosol.
Conclusion Les anesthe´siologistes et les intensivistes
peuvent eˆtre appele´s a` prendre en charge les patients
atteints de MVE. Il est important que les cliniciens
connaissent l’e´pide´miologie et la pathoge´nie de cette
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maladie, ainsi que l’utilisation approprie´e d’un EPI
lorsqu’ils traitent ces patients.
In March 2014, the World Health Organization (WHO)
was notified of an outbreak of Ebola virus disease (EVD),
formerly known as Ebola hemorrhagic fever, in the
forested areas of southeastern Guinea in West Africa.1
The disease subsequently spread to the capital, Conakry,
and then to the neighbouring countries of Liberia, Nigeria,
Sierra Leone, and Senegal. On August 8, 2014, the WHO
declared the epidemic a Public Health Emergency of
International Concern.2
Since the first reports of this most recent outbreak of
EVD, it has spread rapidly and, at last report, had infected
9,936 people with 4,877 deaths.3 Nevertheless, the
trajectory of this epidemic suggests a strong likelihood
that in excess of 1.4 million cases could occur.4 Thus far,
the case fatality rate is 52%, but it ranges from 42% in
Sierra Leone to 66% in Guinea. A significant number of
healthcare workers, including several physicians treating
the patients in Africa, have also contracted the disease and
have succumbed to it. The first reported case in Nigeria,
which does not share a border with any of the other
affected countries, signified the first time air travel was
implicated in the spread of this disease.5 Since the report of
this initial case, one patient with undiagnosed EVD who
returned from Liberia to Dallas, Texas subsequently died of
the disease.6 This was the first case of Ebola in North
America that was not associated with returning healthcare
workers. Subsequent to this case, two nurses in Texas
caring for the Liberian patient contracted the disease, as did
a nurse in Spain whom was caring for two priests who
returned from Africa.7
With both infected and at-risk medical and infectious
disease personnel being transported back to North
America, it is entirely possible that a scenario of active
EVD could occur in Canada. Anesthesiologists, due to their
training in the management of the critically ill, may be
called upon to assist in the management of these patients.
The focus of this brief review is on the epidemiology,
pathogenesis, and management of patients with EVD.
Special attention is given to specific details regarding the
personal protective equipment (PPE) that will be essential
should care for these patients be required.
Virology, epidemiology, and ecology
The Ebola and Marburg viruses are members of the
Filoviridae virus family. These viruses, known to cause
hemorrhagic fever in humans, derive their name from their
long filamentous structure.
Marburg virus, the first known Filovirus, was initially
described in 1967 when imported infected primates from
Uganda introduced the agent into a facility in Marburg,
Germany that was manufacturing a polio vaccine.8 An
infection outbreak characterized by fever, diarrhea,
vomiting, massive bleeding from many different organs,
shock and circulatory system collapse occurred in 31 lab
workers and resulted in a 23% case fatality rate. In recent
years, there have been rare imports of Marburg virus
human infections to Western nations (but without further
propagation).
Ebola virus was first described in an outbreak in the
northwest area of the Democratic Republic of Congo
(formerly known as Zaire) in central Africa in 1976. A
second independent outbreak occurred in the same year
near the town of N’zara in Sudan. All of the subsequent
sporadic outbreaks (with the exception of the present one)
have occurred in this region of central Africa.9 The Ebola
virus is named after a small river in the area where the first
recognized epidemic occurred. Ebola virus has five
genetically distinct species named on the basis of the
geographic region where they were discovered: Zaire
ebolavirus, Sudan ebolavirus, Ivory Coast ebolavirus,
Bundibugyo ebolavirus, and Reston ebolavirus.10,11 The
Zaire and Sudan ebolaviruses have caused the majority of
the outbreaks of EVD, while the Ivory Coast ebolavirus
caused human disease (in 1994) in a worker performing an
autopsy on an infected chimpanzee.12 Bundibugyo
ebolavirus is the most recently described strain from an
outbreak in Uganda in 2007. Reston ebolavirus was first
discovered in 1989 in a facility in suburban Virginia
housing cynomolgus monkeys imported from the
Philippines that were being used to test cosmetics.13
Fortunately, Reston ebolavirus is non-pathogenic to
humans.
The strain of the current outbreak is uncertain. One
genetic analysis of the virus has suggested an altogether
new viral species, termed Guinean Ebola;14 however, other
authorities consider it a sub-strain to Zaire ebolavirus
(personal communication, Gary Kobinger, Chief, Special
Pathogens Branch, National Microbiology Laboratory,
Public Health Agency of Canada, Winnipeg, MB).
The Ebola virus is an enveloped non-segmented
ribonucleic acid (RNA) virus (Fig. 1) with a uniform
diameter but a wide variation in length.15 The viral genome
encodes several proteins, including the replication
machinery of the virus. A soluble glycoprotein encoded
by the viral genome and secreted by infected cells is
thought to prevent the cytopathic effects of the host
immune system on the infected cells.16
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Ebola virus disease is a classic zoonotic disease with
persistence of the virus in a reservoir species in endemic
areas.17 Despite great effort during epidemics, the natural
reservoir or an arthropod vector for Ebola has never been
conclusively proven. Rodents and bats, however, have long
been suspected as being a reservoir for the virus. The
strongest evidence to date implicates fruit and
insectivorous bats as hosts for the virus.18-20 Although
human infection can occur as a consequence of contact
with the carcasses of infected non-human primates (hunted
as a food source), the extremely high mortality in these
animals strongly argues against them as a reservoir.21
The virulence of the different Ebola viruses varies
between strains. Zaire ebolavirus (suspected, though not
yet confirmed, in this recent outbreak) has the highest case
fatality rate of 60-90%, followed by Sudan ebolavirus at
40-60%. It is difficult to determine if these rates would be
seen in the developed world with better access to medical
care. The provision of supportive care to these patients
would likely lessen mortality, particularly when comparing
the 22% case fatality rate seen in the Marburg virus
outbreak in Germany with the 88-90% mortality seen in the
two major African outbreaks.22
Pathogenesis
Research on the pathogenesis of EVD in humans is limited
due to the inaccessibility of the regions where outbreaks
occur. Animal studies of the disease have focused on
primate models.
Ebola virus appears to enter the host through mucosal
surfaces or breaks in the skin, indicating the necessity of
PPE for healthcare workers.17 Infectious viral particles
have been shown in blood, saliva, vomit, feces, urine,
sweat, nasal secretions, and even semen and genital
secretions.23 Once Ebola virus enters a human
population, its spread from person to person requires
direct contact with bodily fluids. Despite the fact that some
aerosolized Filoviruses (Reston ebolavirus) can spread
between non-human primates via the respiratory route,
there is no evidence that this occurs between humans,
which suggests that the virus is not sufficiently
aerosolized.24 Despite this fact, anesthesiologists asked to
perform tracheal intubation on these patients or healthcare
providers who are present during aerosol-generating
medical procedures (AGMP) should take extra
precautions beyond standard PPE (see below).
After entering the body, the Ebola virus initially infects
the dendritic cells and macrophages (Fig. 2). These mobile
cells carry the virus to regional lymph nodes where further
replication occurs.10 From here, the virus is able to travel
via the blood stream and lymphatic channels to the entire
body. During infection, lymphocytes are not directly
infected but undergo high rates of apoptosis. The
resulting lymphopenia leads to a further weakening of the
immune response and allows for unfettered viral
replication.25 Ebola virus is distinct from other viruses in
that it appears to have broad tissue tropism, i.e., it can
infect virtually any cell type in the body.17 The
glycoproteins released by infected cells act as a decoy to
the host’s immune system, soaking up antibodies and
interfering with humoral responses.26 The soluble
glycoprotein also causes direct cytotoxic effects, but the
mechanism of this function has not been elucidated.
The vascular endothelium is thought to play a key role
in the pathophysiology of the disease.27 Capillary leak
caused by an associated systemic inflammatory response
syndrome (SIRS) results in depletion of intravascular
volume. Virally infected macrophages begin to express
tissue factor on their cell surface that then leads to
activation of the coagulation cascade and a consumptive
coagulopathy, i.e., disseminated intravascular coagulation
(DIC) ensues. Direct viral infection of hepatocytes results
in hepatocellular necrosis and a further reduction in levels
of coagulation factors.
Despite its previous name (Ebola hemorrhagic fever)
and descriptions in the lay press of the disease
‘‘liquefying’’ its victims, the hemorrhage related to Ebola
is usually a late manifestation of the disease and is
predominantly gastrointestinal in nature, although
cutaneous and conjunctival hemorrhage may be seen.28
Interestingly, patients infected with Ebola virus have
been shown to increase production of pro-inflammatory
cytokines, including tumor necrosis factor-a, similar to the
response found with SIRS in septic shock.29 Ebola virus
Fig. 1 Ebola virus structure and electron micrograph. Reproduced
with permission from: Mahanty S, Bray M. Pathogenesis of filoviral
haemorrhagic fevers. Lancet Infect Dis 2004; 4: 487-98 10
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infection is also associated with increased blood levels of
nitric oxide (NO), and this has been correlated with
increased mortality.30 In addition to being an important
mediator of hypotension, NO has been associated with
lymphocyte apoptosis and loss of vascular integrity, which
may further contribute to the hypovolemic shock seen in
advanced stages of the disease.
Clinical presentation
The incubation period of EVD has been reported as two to
21 days.17,28,31,32 This wide range in incubation period
may be due, in part, to the lack of reliable information
regarding onset of symptoms in outbreak regions. The most
reliable information on the incubation period for EVD
comes from situations where a well-defined event has
occurred, such as a laboratory or nosocomial exposure. The
average incubation period in most of these cases appears to
be four to ten days.
The different strains of Ebola virus appear to have
somewhat variable distribution of their typical clinical
features. In general, EVD patients typically present acutely
with non-specific symptoms such as cough, rhinorrhea,
chills, headache, myalgia, anorexia, nausea, vomiting, and
diarrhea. Fever is ubiquitous and contributed to the earlier
term for the disease, Ebola hemorrhagic fever.
Temperatures as high as 39-40C are common. The non-
specific initial presentation of EVD leads to a wide
differential diagnosis, including malaria, typhoid, and
other viral hemorrhagic fevers (including Lassa fever)
that occur in the same regions. Unfortunately, by this time,
Fig. 2 Ebola virus pathogenesis: Ebola virus spreads from the initial
infection site to the regional lymph nodes, liver, and spleen. Despite
not being directly infected, lymphopenia is a common feature of the
disease, likely due to apoptosis. Factors released from infected cells
also contribute to capillary leakage as demonstrated here in cultures
of endothelial cells (white arrowheads). The systemic virus spread
leads to hypovolemia, shock, disseminated intravascular coagulation,
and finally multi system organ failure and death. IL = interleukin.
MCP-1 = monocyte chemoattractant protein-1. MIPs = macrophage
inflammatory proteins. NO = nitric oxide. TNFa = tumour necrosis
factor a. Reproduced with permission from: Feldmann H, Geisbert
TW. Ebola haemorrhagic fever. Lancet 2011; 377: 849-62 17
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previously unknown person-to-person transmission is a
major concern.
The subsequent signs and symptoms of the disease are a
manifestation of multisystem organ involvement of the
virus. Prostration, increasing generalized edema, and
severe abdominal pain are common. Neurologic signs
and symptoms include severe headache, confusion, and
decreased level of consciousness, which can be precursors
to seizures and coma. These findings are typically pre-
terminal events. As the disease progresses, worsening of
gastrointestinal symptoms, specifically profound diarrhea
and or vomiting, occur. This can lead to the development of
hypovolemic shock and early death. Cough, chest pain, and
shortness of breath may also occur, but overt respiratory
failure, as is often seen in bacterial sepsis, is not a common
feature of EVD. It is unclear whether this is due to a
significant lack of direct involvement in the respiratory
system or due to the fact that patients in outbreak areas
usually succumb to their disease prior to the occurrence of
respiratory failure.
The ‘‘hemorrhage’’ of this viral hemorrhagic fever is a
late manifestation of the disease, and despite it being
prominently featured in the naming of this disease, it
occurs in only a minority of patients. Massive bleeding is
typically isolated to the gastrointestinal tract; however,
there are also numerous descriptions of conjunctival
hemorrhage, petechiae, purpura, and oozing from
venipuncture sites, typical of DIC.
There have been few reports with respect to typical
laboratory and hemodynamic findings of the disease due to
the austere environment where the disease typically
develops. In the most recent epidemic, Fowler et al.
describe the lack of ability to measure temperature, blood
pressure, and oxygenation, let alone basic laboratory
parameters.28
Nonetheless, when available, laboratory testing shows a
variety of abnormalities. Hemoglobin levels are typically
normal or even elevated in early EVD due to dehydration.
Significant leukopenia with marked lymphopenia and
neutrophilia is common. Thrombocytopenia due to
consumptive coagulopathy and reduced production is also
a typical feature of the disease and frequently meets the
criteria for DIC with platelet counts in the range of
50-100,000 lL-1.17,32,33 Several reports have also
described elevations in partial thromboplastin time and
international normalized ratio.
Elevations of hepatocellular enzymes (two to three times
normal), specifically aspartate and alanine
aminotransferase (AST and ALT), can be seen with
greater elevations being associated with increased risk of
mortality.32,34 This elevation, however, is rarely to the
extent seen in primary viral hepatitis infections and is
almost always AST dominant, suggesting an ischemic/
hypoperfusion etiology. Pancreatic enzymes may also be
elevated.
The most significant laboratory abnormalities relate to
hypoperfusion and the consequences of the severe diarrhea
these patients develop. A mixed metabolic acidosis (normal
and increased anion gap) develops from the diarrhea, and
lactate levels are elevated due to hypoperfusion.
Hypokalemia, due to the diarrhea, is profound and serum
levels less than 2 mEqL-1 have been described.28 This can
lead to serious cardiac arrhythmias and death in a subset of
patients. Acute kidney injury due to hypoperfusion is also
frequently present.
Patients with fatal disease die typically during days six
to16, usually of hypovolemic shock and multi-system
organ failure. In non-fatal cases, patients have fever for
several days and typically begin seeing clinical
improvement during days six to 11. During the Congo
outbreak in 1995, patients who survived to day 14 had a
greater than 75% chance of survival.35
Diagnosis
At present, the gold standard for clinical diagnosis of EVD
is real-time polymerase chain reaction (RT-PCR). Antigen
detection with an enzyme-linked immunosorbent assay is
also used. The RT-PCR testing of patient samples in the
endemic West African areas is being performed in the field
and, ironically, is sometimes the only laboratory testing
available for patients.28
Management
Prior to any possible hospital encounter with EVD, each
facility should have a plan in place that specifically covers
where these patients will be cared for, who will be caring
for them (from both a physician and a nursing perspective),
and detailed protocols for PPE utilization. The necessity for
advanced planning and practice by facilities and clinicians
that may be caring for these patients cannot be stressed
enough. It is extremely important to have a high degree of
familiarity with the required care procedures in order to
lessen the chances of infecting healthcare workers.
The World Health Organization, the United States
Centers for Disease Control and Prevention, and the
Public Health Agency of Canada have each published
Ebola clinical care guidelines for healthcare workers which




focus of the remainder of this article is on the clinical care
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of EVD patients, with special attention devoted to those
areas where anesthesiologists may be involved with these
patients (resuscitation and airway management).
Patient care and personal protection
Patients with EVD should be cared for in a single-patient
room that is physically separated from other patient care
areas. The patient’s room should have a private anteroom
for donning and removing the PPE as well as washing
facilities. Ideally, the patient room should have negative
pressure isolation, particularly if clinicians will be
performing aerosol-generating medical procedures
(AGMP). The ability to dispose of patient’s body fluids
inside the room should also be present. Suction, monitors,
medical gas connections, and adequate space for life
support equipment should also be present. In most
hospitals, the intensive care unit is the most practical
place for the care of EVD patients. Ideally, as few people
as possible should be involved in the direct care of these
patients.
It is important to have a thorough understanding of the
current guidelines that outline the minimally acceptable




Healthcare staff must wear disposable water-resistant
coveralls (preferably with a hood), a waterproof apron or
impermeable gown, an N95 mask, a disposable full-face
shield, two sets of gloves, and impermeable foot and leg
coverings. While current guidelines suggest the adequacy
of a well-fitted N95 mask, we recommend that clinicians
use a powered air purifier respirator suit (PAPR) when
performing AGMP such as airway suctioning or intubation.
This adds an additional layer of protection and provides
high-efficiency particulate air (HEPA) filtering as well as
fresh air to the clinician (Fig. 3). There are logistical and
practical issues with the use of PAPR suits that may limit
their use (see below).
Invasive monitoring
The decision to institute invasive monitoring should be
carefully considered with respect to the benefit to the
patient and the risk to the healthcare staff. While significant
bruising and ecchymosis may result from repeated
noninvasive blood pressure measurements, the institution
of invasive arterial blood pressure monitoring places
healthcare workers at risk for contamination in the case
of a circuit disconnection or leak. If arterial monitoring is
implemented, access should be avoided through the
femoral area due to the frequency of soiling in the region.
Similarly, centrally or peripherally inserted central
catheters should not be placed for the purpose of central
venous pressure monitoring alone, as this has been shown
to be of limited clinical utility, and its validity as a marker
of preload has been questioned.36,37 All of the following
indications would be appropriate for placement of a central
venous cannula: to ensure low-risk access to blood
samples, to deliver electrolyte replacement, to administer
vasoactive medications, or to utilize central venous
oxygenation saturation as a marker for cardiac output.38
If the decision is made to place a central cannula,
experienced clinicians should conduct the procedure,
ensuring to employ ultrasound guidance.39,40
Consideration should be given to the use of non-suture
securing devices to minimize the number of skin punctures
and the potential for needle stick injury. Needle-less
systems, whether used for peripheral or central venous
access, should be used at all times.
Clinical treatment
The mainstay of the treatment of EVD is aggressive
resuscitation with intravenous fluids and correction of
electrolyte abnormalities. Adequate intravenous access is
necessary for fluid resuscitation of these patients as they
will likely be hypovolemic from significant diarrhea.
Where possible, it is important to stay ahead of volume
Fig. 3 Powered air purifying respirator (PAPR) hood
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losses rather than merely reacting to clinical signs of
hypovolemia.
Ringer’s lactate (RL) is the preferred solution for a
number of reasons. When compared with resuscitation with
normal saline, RL causes less acidosis, kidney injury, and
bleeding.41-43 The hyperchloremia that typically ensues
after normal saline administration has also been associated
with increased mortality.44 The additional acidosis that
results from normal saline administration in these patients
may be particularly problematic, as the metabolic acidosis
caused by the diarrhea may render patients unable to
maintain an adequate minute ventilation to maintain a
normal pH, especially in the setting of hypokalemia which
may weaken respiratory muscles.
Based on extrapolated data from patients with Dengue
fever and those with septic shock, colloid solutions
(including synthetic starches and human albumin) do not
have a role in the resuscitation of patients with EVD, as
they have shown no evidence of efficacy and have the
potential for adverse renal outcomes.45-48
As patients with Ebola virus may progress to DIC, the
need for transfusion of coagulation factors may become
necessary. Transfusion of coagulation factors and platelets
should be reserved for those patients who are clinically
bleeding, as there is no evidence of benefit for prophylactic
transfusions.49
As mentioned previously, severe electrolyte
abnormalities, most notably hypokalemia, are likely to
occur in patients with EVD. Enteral replacement is the
preferred method, but in patients with severe nausea and
vomiting, intravenous replacement may be required. If this
is the case, it should be done via the central route.
Airway management
While primary respiratory failure is not a usual feature of
EVD, secondary causes might occur, including shock,
acute lung injury, fluid overload, respiratory muscle fatigue
(from electrolyte disturbances and respiratory acidosis),
and transfusion-related acute lung injury. In these
situations, anesthesiologists may become involved, as
only the most skilled practitioners in this area should
perform any airway manipulation.
Noninvasive positive pressure (NIPPV) ventilation is
relatively contraindicated due to the high incidence of
vomiting and hematemesis and the risk of aspiration in
these patients. Also, NIPPV may result in prolonged
aerosolization of fluids containing the virus, placing
caregivers at prolonged risk for contracting Ebola virus
infection.
Ideally, endotracheal intubation should be performed
only in an elective or semi-elective fashion. This
minimizes the chances of error that might occur
when donning PPE for the urgent care of a deteriorating
patient.
The addition of a PAPR suit should be strongly
considered when performing endotracheal intubation on
these patients. Although a well-fitted N95 mask and face
shield is minimally adequate according to current
guidelines, a PAPR unit may provide better protection
from aerosolized virus-containing fluids than an N95 mask
and it is also more comfortable.
When compared with an N95 mask, PAPR suits have
enhanced filtration ability due to their built-in HEPA filter.
Also, positive airflow from inside to outside the PAPR suit
forces contaminated air away from the user. Further,
unlike N95 masks, no special fit testing is required for
PAPR suits.
The advantages of PAPR suits must be balanced against
several potential disadvantages. First, not every institution
will have access to PAPR suits, as they are not common
equipment in the healthcare setting. Second, the PAPR unit
requires testing before use in order to ensure proper
functioning. This necessarily delays donning the suit and
may be disadvantageous when clinicians must respond in a
timely fashion to a critically ill patient with EVD. Finally,
removing PAPR suits is more complicated than removing
the recommended basic PPE. As a result, the clinician
could potentially be contaminated during the removal of
the suit.
The risks of using these suits must be balanced against
the benefits. Several important points must be emphasized
regarding this subject. First, clinicians must practice
putting on and removing the suits prior to actual contact
with an EVD patient. This should be done in cooperation
with the department responsible for infection prevention
and control, and a checklist protocol should be developed
to ensure that it is done precisely and with exacting
standards each and every time. The procedures for putting
on and removing PPE are outlined in the Appendix.
Regular practice sessions should occur to keep clinicians
familiarized with the proper PAPR suit procedures.
Second, as the WHO or the Centers for Disease Control
and Prevention do not recommend PAPR suits as part of
PPE, clinicians may not want to utilize them as they are
cumbersome to remove. It is the removal of PPE that has
caused the majority of cases of EVD transmission to
healthcare workers, and PAPR suits add another layer of
complexity to PPE removal.
Even though respiratory transmission of EVD has not
been confirmed, rapid sequence intubation with the use of
neuromuscular blocking agents is highly recommended to
reduce the risk of coughing with aerosolization. Further,
patients requiring tracheal intubation may have
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hematemesis or may vomit, increasing the risk of viral
transmission to healthcare workers. To lessen the risk of
transmission during intubation, the minimum number of
required personnel should be in attendance in the room.
Specific therapy and vaccination
At present, no specific therapy or vaccine is effective for
EVD. Typical antivirals, such as ribavirin, have not shown
efficacy when given to infected humans. Similarly, no
other currently available agents have been successful in
animal models of EVD.50,51 There have been numerous
experimental therapies in non-human primates with
variable success. These include recombinant human
activated protein C, RNA interference with
oligonucleotides, and human convalescent serum.52
During this most recent outbreak, several healthcare
workers were treated with an experimental drug, ZMapp
(Mapp Biopharmaceutical, San Diego, CA, USA). This
drug is a combination of three monoclonal antibodies with
known neutralizing activity against EVD that has been
produced in genetically modified tobacco plants. This
approach yielded 100% protection in a primate model
within five days of infection challenge.53 Two American
patients who were administered this drug survived, but
both a Liberian physician and a Spanish clergyman who
were given the drug during the same outbreak succumbed
to the disease. At present, ZMapp is considered
experimental therapy, and the current supply of the drug
will limit its large-scale use for the immediate future.
Recently, the WHO has supported the use of
convalescent blood, serum, or hyperimmune globulin
from survivors of Ebola virus infection as an
experimental therapy. Although there is no proven utility
with respect to EVD, historical data with other severe viral
infections and limited human studies with EVD suggest
possible efficacy.54,55
Post-exposure prophylaxis with a recombinant vaccine,
based on the vesicular stomatitis virus, has shown
remarkable usefulness in non-human primates,56,57 but
human trials have only just begun and have not reported
results. Previously, the utility of developing an Ebola
vaccine had been disputed due to the disease’s rarity and
potential cost of development. Nevertheless, the increased
frequency of outbreaks, case reports of ‘‘imported’’ viral
hemorrhagic fevers in travellers, and the potential misuse of
the virus as a bioterror agent have altered this viewpoint. At
present, several other candidate vaccines have been
developed but have not been tested in humans due to
safety and ethical concerns.58-60 Their development has
been accelerated in view of the severity of the current
epidemic.
Summary
Ebola virus disease is a highly transmissible highly fatal
viral hemorrhagic fever. Anesthesiologists, with their
training in the management of the critically ill, may be
called upon to assist in the management of these patients,
either for intubation, or to assist with resuscitation. As
there is no approved therapy for EVD, the meticulous use
of PPE is required for all patient contact.
The chance of an EVD patient presenting to any given
hospital is unquantifiable; therefore, it is essential that clinicians
have an understanding of this disease. Hospitals should have
protocols in place to deal with patients with this disease or other
highly transmissible and fatal infectious diseases.
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Appendix: Putting on and removing personal protective
equipment (PPE)
Equipment required
• Disposable (or non-disposable to be destroyed) scrubs
• Fluid-resistant coveralls with attached hood
• Impermeable gown
• Long gloves with secure cuff 92




• Closed toe and heel shoes (dedicated to unit)
• Basin for Oxivir TB RTU solution 9 3 (2 in anteroom,
1 in patient room)
• Mayo stand to support basin with solution in patient
room
• Tape for marking anteroom floor (identify space for
contaminated staff and assist staff)
• Walk-off mat for disinfectant
Donning PPE
• On arrival to unit, change into disposable scrubs and
dedicated shoes in change room
• Remove jewellery, lanyards, and so on
• Securely tie hair back if required
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Outside patient room (for entry)
1. Perform hand hygiene (HH). Alcohol-based hand rub
(ABHR) is acceptable unless visible soiling is present;
soap and water required if soiling present
2. Put on 1st set of gloves
3. a. Put on coveralls; close zipper; pull hood securely
onto head
b. Ensure 1st set of gloves is under sleeves of coveralls
4. Put on shoe/leg coverings
5. a. Put on impermeable gown
b. Ensure gown covers backside. If not covered
completely, first don a gown as a housecoat, and
then put on the second gown as usual.
6. Put on N95 respirator/mask over hood
7. Put on full-face shield over hood
8. Put on 2nd set of gloves over impermeable gown;
ensure cuffs of gloves are secure over cuff of gown
9. Trained monitor to confirm appropriate PPE
application/fitting before individual enters anteroom
Removing PPE
2nd person (assistant) PPE: disposable (or non-disposable to
be destroyed) scrubs; impermeable gown; gloves 91;
procedure/surgical mask; full-face shield
• Assistant to immerse gloves and to rub together
carefully in Oxivir TB RTU solution after each
contact with the primary individual
• Assistant can remove their PPE alone; assistance from
primary with untying gown may be needed
• If assistant to aide multiple individuals (i.e., one after
another), new PPE required between each person being
assisted
Exiting patient room
Only 1 person at a time shall exit the patient room. PPE
must be removed completely, and the anteroom must be
exited before the next person enters the anteroom.
1. In patient room, immerse gloved hands into basin and
carefully rub together; wipe door handle with Oxivir
TB wipe; allow 1 minute drying time before exiting
the patient room
2. Enter the anteroom staying in the half of the room
closest to the patient room (delineated by tape);
ensure contact with walk-off mat
a. Immerse gloved hands into basin and carefully rub
together in Oxivir TB RTU solution
3. After door closes, 2nd person (assistant) to enter the
anteroom staying on the half closest to hallway
4. Remove outer set of gloves using glove-to-glove
skin-to-skin technique
5. Immerse gloved hands into basin and carefully rub
together in Oxivir TB RTU solution
6. Remove gown (with assistance if needed)
7. Immerse gloved hands into basin and carefully rub
together in Oxivir TB RTU solution
8. Remove shoe/leg coverings (with assistance if
needed)
9. Immerse gloved hands and carefully rub together in
Oxivir TB RTU solution
10. Remove face shield (by strap behind head)
11. Immerse gloved hands and carefully rub together in
Oxivir TB RTU solution
12. Remove N95 respirator/mask by straps behind head
and with eyes closed
13. Immerse gloved hands and carefully rub together in
Oxivir TB RTU solution
14. Remove coveralls with assistance
a. Assistant to unzip coveralls carefully to lower
abdomen by pulling front area of coveralls
downwards, tilting head upwards, and continuing to
unzip
b. Using outside of hood, assistant to uncover hood
carefully from head
c. Assistant to peel suit downwards to expose
shoulders, allowing hood to be further away from neck
d. Using outside of sleeves, assistant to remove one
sleeve at a time. Carefully roll coveralls downward in a
manner avoiding contamination of disposable scrubs.
Remove coveralls
15. Immerse gloved hands and carefully rub together in
Oxivir TB RTU solution
16. Remove inner set of gloves
17. Perform HH (ABHR acceptable unless visible soiling
present; if present, soap and water required)
18. Once 2nd person has removed PPE, exit anteroom.
Primary may exit at the same time
Wash gloves/perform hand hygiene whenever possible
hand contamination has taken place, at any point during
PPE removal.
Assistant PPE removal
1. Remove gloves using glove-to-glove skin-to-skin
technique
2. Remove gown
3. Untie neck, then waist
4. Hook fingers under opposite cuff; pull over hand
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5. Use gown-covered hand to pull gown over other hand
6. Pull gown off without touching outside of gown
7. Roll up inside out and carefully dispose
8. Perform HH (ABHR acceptable unless visible soiling
present; if present, soap and water required)
9. Remove face shield (by strap behind head)
10. Remove mask by loops/straps behind ears/head. Do
not touch front of mask
11. Perform HH (ABHR acceptable unless visible soiling
present; if present, soap and water required)
Perform hand hygiene whenever possible hand
contamination has taken place, at any point during PPE
removal.
Exiting patient room checklist (primary)
Only 1 person at a time shall exit the patient room. PPE
must be removed completely and anteroom must be exited
before next person enters the anteroom.
1. In patient room, immerse gloved hands into basin and
carefully rub together
2. Wipe door handle with Oxivir TB wipe; allow 1
minute dry time before exiting the patient room
3. Enter anteroom staying in the half of the room closest
to the patient room (delineated by tape); ensure
contact with walk-off mat
4. Immerse gloved hands into basin and carefully rub
together
5. After door closes, 2nd person to enter staying in the
half closest to hallway
6. Remove outer set of gloves using glove-to-glove,
skin-to-skin technique
7. Remove gown (with assistance if needed)
8. Immerse gloved hands into basin and carefully rub
together
9. Remove shoe/leg coverings (with assistance if
needed)
10. Immerse gloved hands and carefully rub together in
Oxivir TB RTU solution
11. Remove face shield (by strap behind head)
12. Immerse gloved hands and carefully rub together in
Oxivir TB RTU solution
13. Remove N95 respirator/mask by straps behind head
and with eyes closed
14. Immerse gloved hands and carefully rub together in
Oxivir TB RTU solution
15. Remove coveralls with assistance
a. Assistant to unzip coveralls carefully to lower
abdomen by pulling front area of coveralls
downwards, tilting head upwards, and continuing to
unzip
b. Using outside of hood, assistant to uncover hood
carefully from head
c. Assistant to peel suit downwards to expose
shoulders, allowing hood to be further away from
neck
d. Using outside of sleeves, assistant to remove one
sleeve at a time. Carefully roll coveralls downward in
a manner avoiding contamination of disposable
scrubs. Remove coveralls
16. Immerse gloved hands and carefully rub together in
Oxivir TB RTU solution
17. Remove inner set of gloves
18. Perform HH. ABHR acceptable unless visible soiling
present; if present, soap and water required
19. Once 2nd person has removed PPE, exit anteroom.
Primary may exit at the same time
Wash gloves/perform HH whenever possible hand
contamination has occurred, at any point during PPE
removal.
Exiting patient room checklist (assistant)
Only 1 person at a time shall exit patient room. PPE must
be removed completely and anteroom exited before the
next person enters the anteroom.
1. Remove gloves using glove-to-glove skin-to-skin
technique
2. Remove gown
3. Untie neck, then waist
4. Hook fingers under opposite cuff; pull over hand
5. Use gown-covered hand to pull gown over other hand
6. Pull gown off without touching outside of gown
7. Roll up inside out and carefully dispose
8. Perform HH (ABHR acceptable unless visible soiling
present; if present, soap and water required)
9. Remove face shield (by strap behind head)
10. Remove mask by loops/straps behind ears/head. Do
not touch front of mask
11. Perform HH (ABHR acceptable unless visible soiling
present; if present, soap and water required)
Wash gloves/perform HH whenever possible hand
contamination has occurred, at any point during PPE removal.
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